Genmab — December 2020
-
New DARZALEX
(daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma https://www.prnewswire.com/news-releases/new-darzalex-daratumumab-data-from-griffin-study-show-deeper-and-longer-responses-in-patients-with-newly-diagnosed-multiple-myeloma-301187387.html -
Data from the ANDROMEDA Study Show Hematologic Response for DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj) in Newly Diagnosed Light Chain (AL) Amyloidosis https://www.prnewswire.com/news-releases/data-from-the-andromeda-study-show-hematologic-response-for-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-newly-diagnosed-light-chain-al-amyloidosis-301187390.html -
-
FiercePharma -ASH: Johnson & Johnson shores up Darzalex's myeloma lead with another subcutaneous win https://www.fiercepharma.com/pharma/ash-johnson-johnson-shores-up-darzalex-s-myeloma-lead-another-subcutaneous-win
-
Dr Mark Wildgust: GRIFFIN Findings Show Adding Daratumumab to Induction, Maintenance Regimens Improves Rate, Depth of Response https://www.ajmc.com/view/dr-mark-wildgust-griffin-findings-show-adding-daratumumab-to-induction-maintenance-regimens-improves-rate-depth-of-response
-
Bloomberg Markets @markets
Biotech stocks rallied to a record Monday in reaction to a deluge of data on blood disease treatments presented at the American Society of Hematology https://trib.al/dm8Ce0l -
De er åbenbart også i vildrede i US.
-
GMAB i minus.
-
Data var gode og det skal nok drive kursen fremover. I dag og andre dage kan det være andre ting, der driver kursen. US omsætningen er kun 1/10 af DK omsætningen og derfor noget man ikke skal hænge sig så meget i. Husker US faldt den aften vi fik daras første pivotal trial offentliggjort. Dagen efter var der fest i Kbh
-
Som sædvanlig skal man glemme dagens kurs og hvile i sin forvisning om at de sidste dages data vil betyde langt højere kurser i løbet af de næste par år. Tålmodighed.. og ikke al det der "uha-idag-skulle-vi-ned-på-gode-nyheder-er-der-nnoget-galt-?" !!
-
https://www.linkedin.com/posts/genmab_ash20-duobody-activity-6741818830106034176-KJbL Et eller andet sted skulle man kunne høre mere om epco
-
Morn fra BKK
Har for en ordens skyld lige checket 2020 kursstigning og ja genmab kursen er p.t steget 58% i år siden 1 Januar så personligt er jeg rimlig godt tilfreds. Kunne selvfølgelig være fedt med 100% hvert år men en gang imellem må man nøjes med 15-60%. Godt nok er Genmab en fantastisk aktie men fremadrettet tror jeg vi skal være glade for 20-30% kursstigning per år så mon ikke kurs 3000 er muligt inden udgang af 2021 -
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind